Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

ization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(TM). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) -- the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit http://www.middlebrookpharma.com.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on MiddleBrook's current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited to, statements about the Company's future development plans, clinical trials, potential commercial success, and any financial forecasts included in this announcement.

The actual results realized by MiddleBrook could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's fil
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... On Thursday, September 11, 2014, the NASDAQ Composite ... finished the day 0.12% lower at 17,049.00, and the S&P ... based as seven out of ten sectors ended the session ... the day at 741.83, down 0.33%, while the index has ... coverage on the following equities: Exelixis Inc. (NASDAQ: ...
(Date:9/11/2014)... RURO, Inc., a leading laboratory ... and sample management solutions provider, announces the release ... on the most recent version of its Limfinity® ... seen mass adoption, especially from multi-license environment customers. ... brought an entirely new User Interface and version ...
(Date:9/11/2014)... Lab researchers believes it has uncovered the secret ... layers of transition metal dichalcogenide (TMDC) materials, the ... and photonic applications. , Using two-photon excitation ... one of the most promising of 2D materials, ... dark states energy states in which single ...
(Date:9/11/2014)... one atom thick sheet of carbon, can be randomly ... of graphene that could have a significant impact on ... it could provide an ultra-strong, non-corrosive coating for a ... solutions can be used to paint various surfaces ranging ... a simple chemical treatment, the resulting coatings behave like ...
Breaking Biology Technology:Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 2Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 3Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 4Technical Coverage on Biotech Stocks - Exelixis, Arena Pharma, Novavax, Dendreon, and Amicus Therapeutics 5Limfinity® Version 5.1 Available 2Excitonic dark states shed light on TMDC atomic layers 2Excitonic dark states shed light on TMDC atomic layers 3Graphene paints a corrosion-free future 2
... (OTCBB:IAGX) announced today it has appointed Bill Toomey to ... the appointment, Mr. William Spencer, Imagenetix Chief Executive Officer ... join our board and bring to us his extensive ... benefit greatly from his past experiences and high level ...
... BELL, Pa., June 30, 2011 Inovio Pharmaceuticals, Inc. ... the development of therapeutic and preventive vaccines against cancers ... compelling immune responses in a study of its multi-subtype ... proprietary vaccine delivery technology in sheep, the second large ...
... ORLEANS, June 29, 2011 Ochsner Health System has signed ... e ICU Program to enhance critical care -- a program ... of stay and save lives. As the only healthcare provider ... Ochsner will serve as a statewide resource to community and ...
Cached Biology Technology:Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors 2Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 2Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 3Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 4Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 5Inovio Pharmaceuticals' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study 6Ochsner Health System will Offer First eICU Program in Louisiana 2Ochsner Health System will Offer First eICU Program in Louisiana 3
(Date:9/15/2014)... million years after it formed may have been surprisingly ... and active crustal plates. , This alternate view of ... substantial new support from the first detailed comparison of ... ago with those formed contemporaneously in Iceland, which has ... Earth. , The study was conducted by a team ...
(Date:9/15/2014)... is no published account where hippopotamuses are demonstrably shown ... of water. But if they can,t swim, how did ... widely accepted models for the methods, patterns, and timing ... Cyprus, Crete, and Madagascar) may need to be reconsidered. ... the mainland are not currently supported by positive ...
(Date:9/15/2014)... the proteins in our cells cooperate with one another. ... of thousands of different proteins find the correct dancing ... body, brain and nervous system. A recent breakthrough at ... down the door and provided a look at the ... Professor emeritus Jens Jrgen Led of the University of ...
Breaking Biology News(10 mins):Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3Protein courtship revealed through chemist's lens 2Protein courtship revealed through chemist's lens 3
... at the second European Lung Cancer Conference shows ... small-cell lung cancer benefit in terms of overall ... Patients treated with hyperfractionated or accelerated radiotherapy ... over a shorter period of time. The benefit ...
... radiotherapy using real-time X-ray images has allowed French doctors to ... liver cancers while minimizing harm to nearby healthy tissue, researchers ... this study we show that it is possible and very ... at any time before or during treatment in terms of ...
... In this latest image acquired by ESA,s Envisat on Thursday ... Gulf of Mexico can be seen as a dark blue ... the oil spill five times larger than first estimated ... coast, threatening environmental disaster. , As efforts are being made ...
Cached Biology News:Meta-analysis: Radiotherapy variants improve survival in non-metastatic lung cancer 2Oil spill in the Gulf of Mexico nears the coast 2
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
...
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Biology Products: